TITLE

Few oncologists told patients about benefits, risks of palliative chemotherapy

PUB. DATE
September 2008
SOURCE
Hem/Onc Today;9/10/2008, Vol. 9 Issue 16, p36
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article explains the results of the study on the amount of information given by oncologists to patients about the benefits and risks of palliative chemotherapy. Researchers from the University of Bristol, University Hospitals Bristol NHS Foundation Trust, and Weston Area Healthcare Trust in the Great Britain discovered that the amount of data physicians provide their patients about the therapy could extend their lives, with time frames between four weeks and a couple of months. The researchers believe that the patients' expectations must be noted.
ACCESSION #
34154573

 

Related Articles

  • Lung Cancer Update.  // PharmaWatch: Cancer;Sep2005, Vol. 4 Issue 9, p9 

    The article presents news briefs related to developments in the field of lung cancer treatment. The Canadian health authorities have approved OSI Pharmaceuticals, Genentech and Roche's Tarceva for the treatment of locally advanced or metastatic non-small cell lung cancer in patients who have not...

  • When is treatment for cancer economically justified? Discussion paper. Jennett, B.; Buxton, M. // Journal of the Royal Society of Medicine;Jan1990, Vol. 83 Issue 1, p25 

    The article discusses issues related to the economically justified treatment for cancer. Patients go through different medical treatments like radiation, and curative or palliative chemotherapy, but these treatments do not provide much benefit to the patients. Oncologists use chemotherapy for...

  • Patients not told of potential benefits of palliative therapy.  // Nursing Standard;10/29/2008, Vol. 23 Issue 8, p15 

    The article offers information on a study done by researchers in Bristol, England to examine how much oncologists told patients about the survival benefits of palliative chemotherapy during consultations when treatment decisions were being made. The study showed that the amount of information...

  • Perspectives and Attitudes on the Use of Adjuvant Chemotherapy and Trastuzumab in Older Adults with HER-2 Breast Cancer: A Survey of Oncologists. HURRIA, RTI; WONG, F. LENNIE; PAL, SUMANTA; CHUNG, CATHIE T.; BHATIA, SMITA; MORTIMER, JOANNE; SOMLO, GEORGE; HURVITZ, SARA; VILLALUNA, DOOJDUEN; NAEIM, ARASH // Oncologist;Sep2009, Vol. 14 Issue 9, p883 

    Background. Substantial evidence supports the use of adjuvant trastuzumab with chemotherapy for patients with human epidermal growth factor receptor (HER)-2+ breast cancer; however, a lesser amount of data is available to guide use of this therapy in older patients and in those with significant...

  • Pediatric oncologist here leads bone-cancer trial. Hesse, Jennifer // Journal of Business (10756124);6/17/2004, Vol. 19 Issue 13, pB3 

    Reports on the study of a new method for treating patients who suffer from a rare form of bone cancer by pediatric oncologist Judy Felgenhauer sponsored by cancer research organization Children's Oncology Group. Schedule of the enrollment for eligible patients; Evaluation of the side effects...

  • The views and practice of oncologists towards nutritional support in patients receiving chemotherapy. Spiro, A.; Baldwin, C.; Patterson, A.; Thomas, J.; Andreyev, H. J. N. // British Journal of Cancer;8/21/2006, Vol. 95 Issue 4, p431 

    Malnutrition in patients with cancer is common and an adverse prognostic indicator. A questionnaire answered by 357 (72%) UK specialist oncological trainees suggests that they lack the ability to identify factors that place patients at risk from malnutrition. Major barriers to effective...

  • Combination chemo offers NHL survival.  // New Zealand Doctor;8/11/2004, p16 

    Reports on the findings of a study conducted by the American Society of Clinical Oncology which deals with the survival rate of patients below sixty five years with aggressive non-Hodgkin's lymphoma (NHL) after treatment with a combination of rituximab and chemotherapy. Percentage of survival...

  • Clinical Correspondence. Tierra, Michael; Bergner, Paul // Medical Herbalism: A Journal for the Clinical Practitioner;Spring2006, Vol. 15 Issue 1, p17 

    The author presents his report on the case of an advanced bile duct cancer patient. The patient is in stage II of cholangiocarcinoma with metastasis to the liver and is diagnosed by his oncologist to have less than a 1% survival potential. He states that the combined use of herbal and natural...

  • Prevention reduces oral mucositis. Jesitus, John // Dermatology Times;May2006, Vol. 27 Issue 5, p74 

    The article discusses the preventive measures that reduce oral mucositis to patients who undergo chemotherapy treatments. The patients who are about to start the chemotherapy must consult to a dentist to address any oral hygiene issues. They are advised to brush their teeth two or three times a...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics